Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation

Haploidentical stem cell transplantation (haploSCT) offers an alternative treatment option for advanced leukemia patients lacking a HLA‐compatible donor. Transfer of NK cells represents a promising therapeutic option in combination with SCT, as NK cells can promote graft versus leukemia with low risk of GVH disease. In this study, we show results from a phase I/II trial in which 24 acute myeloid leukemia patients underwent haploSCT in combination with early transfer of unmodified NK cells and observed a promising 2‐year overall survival rate of 37%. By performing immunomonitoring and subsequent principal component analysis, we tracked donor NK‐cell dynamics in the patients and distinguished between NK cells reconstituting from CD34+ precursors, giving rise over time to a continuum of multiple differentiation stages, and adoptively transferred NK cells. Transferred NK cells displayed a mature phenotype and proliferated in vivo during the early days after haploSCT even in the absence of exogenous IL‐2 administration. Moreover, we identified the NK‐cell phenotype associated with in vivo expansion. Thus, our study indicates a promising path for adoptive transfer of unmodified NK cells in the treatment of high‐risk acute myeloid leukemia.

[1]  C. Romagnani,et al.  Signatures of Human NK Cell Development and Terminal Differentiation , 2013, Front. Immunol..

[2]  R. Handgretinger,et al.  Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. , 2013, Cytotherapy.

[3]  P. Ljungman.  CMV: a warrior against leukemia? , 2013, Blood.

[4]  B. Sandmaier,et al.  CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. , 2013, Blood.

[5]  L. Moretta,et al.  Human NK cell receptors/markers: A tool to analyze NK cell development, subsets and function , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[6]  J. Trowsdale,et al.  NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. , 2013, Blood.

[7]  A. Gratwohl,et al.  Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers , 2013, Bone Marrow Transplantation.

[8]  Jeffrey S. Miller,et al.  Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen , 2012, The Journal of Immunology.

[9]  A. Velardi.  Natural killer cell alloreactivity 10 years later , 2012, Current opinion in hematology.

[10]  R. Handgretinger,et al.  Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation , 2012, Annals of the New York Academy of Sciences.

[11]  L. Lanier,et al.  Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. , 2012, Blood.

[12]  T. Asselah,et al.  CMV drives clonal expansion of NKG2C+ NK cells expressing self‐specific KIRs in chronic hepatitis patients , 2012, European journal of immunology.

[13]  F. Locatelli,et al.  Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? , 2012, Blood.

[14]  H. Liao,et al.  G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT , 2012, Bone Marrow Transplantation.

[15]  M. Baccarani,et al.  Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. , 2011, Blood.

[16]  P. J. Norris,et al.  Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection , 2011, Proceedings of the National Academy of Sciences.

[17]  F. Locatelli,et al.  Human NK receptors: From the molecules to the therapy of high risk leukemias , 2011, FEBS letters.

[18]  H. Ljunggren,et al.  Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. , 2010, Blood.

[19]  H. Pircher,et al.  CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. , 2010, Blood.

[20]  A. Thiel,et al.  CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. , 2010, Blood.

[21]  P. Debré,et al.  NK Cell Terminal Differentiation: Correlated Stepwise Decrease of NKG2A and Acquisition of KIRs , 2010, PloS one.

[22]  C. Pui,et al.  NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Caligiuri,et al.  CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. , 2010, Blood.

[24]  L. Xu,et al.  Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors , 2009, Bone Marrow Transplantation.

[25]  K. Hsu,et al.  Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. , 2009, Blood.

[26]  M. Martinetti,et al.  Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. , 2009, Blood.

[27]  Arnon Nagler,et al.  A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. , 2008, Blood.

[28]  M. Sormani,et al.  Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. , 2008, Blood.

[29]  T. Kuijpers,et al.  Human NK cells can control CMV infection in the absence of T cells. , 2008, Blood.

[30]  L. Kanz,et al.  Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. , 2008, Blood cells, molecules & diseases.

[31]  E. Thiel,et al.  The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. , 2007, Transplant immunology.

[32]  F. Aversa,et al.  Competing risk analysis using R: an easy guide for clinicians , 2007, Bone Marrow Transplantation.

[33]  S. Gasser,et al.  Activation and self‐tolerance of natural killer cells , 2006, Immunological reviews.

[34]  C. Mecucci,et al.  Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Debré,et al.  NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. , 2005, Blood.

[36]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[37]  E. Thiel,et al.  CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets , 2005, Leukemia.

[38]  E. Lanino,et al.  Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). , 2005, Blood.

[39]  Chi-kong Li,et al.  Elevated Serum Interleukin-15 Level in Acute Graft-Versus-Host Disease After Hematopoietic Cell Transplantation , 2003, Journal of pediatric hematology/oncology.

[40]  D. Ligeiro,et al.  Haploidentical stem cell transplantation with purified CD34 cells after a chemotherapy-alone conditioning regimen. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[41]  M. Caligiuri,et al.  The biology of human natural killer-cell subsets. , 2001, Trends in immunology.

[42]  T. Okamura,et al.  Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease , 2001, Bone Marrow Transplantation.

[43]  H. Lazarus,et al.  Genetically haploidentical stem cell transplantation for acute leukemia , 2001, Bone Marrow Transplantation.

[44]  A. Tosti,et al.  Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. , 1999, Blood.

[45]  M. Minegishi,et al.  Prolonged secretion of IL-15 in patients with severe forms of acute graft-versus-host disease after allogeneic bone marrow transplantation in children. , 1998, International journal of hematology.

[46]  P. Ljungman.  Immune reconstitution and viral infections after stem cell transplantation. , 1998, Bone marrow transplantation.

[47]  F. Prósper,et al.  Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections. , 1997, Blood.

[48]  A. Barrett,et al.  10 Graft-versus-leukaemia , 1997 .

[49]  M. Oudshoorn,et al.  HLA gene haplotype frequencies in bone marrow donors worldwide registries. , 1997, Human immunology.

[50]  F. Aversa,et al.  Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. , 1994, Blood.